News

404

Immunophotonics’ Fast-Track Grant from NIH’s National Cancer institute was granted approval to transition from Phase I to Phase II

Immunophotonics’ Fast-Track Grant from NIH’s National Cancer institute was granted approval to transition from Phase I to Phase II

Immunophotonics was recently granted approval by the NIH’s National Cancer Institute to transition from Phase I to Phase II Fast-track grant from Small Business Innovative Research (SBIR) for research regarding use of the company’s lead drug candidate, IP-001, in nonclinical models of Hepatocellular Carcinoma (HCC) in conjunction with thermal tumor ablation by microwave. This research...

Immunophotonics Announces 1st Patient Dosed in Multinational Clinical trial in France

Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in a multinational clinical trial in France at Hôpital Foch in Suresnes.  The protocol has been approved within the United States, United Kingdom, Switzerland, France, and Germany and will have over a dozen sites participating.  The principal objective of this study is to...

RESI Boston 2023 – September 18th

Immunophotonics Co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Boston attending the RESI Boston 2023, September 18th, at Boston Park Plaza.

CIRSE 2023 September 9 – 13, 2023

Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be at Booth F18 at the CIRSE 2023 Conference, September 9 – 13 in Copenhagen, Denmark.  They are excited to discuss how Immunophotonics is advancing the novel concept of abscopalizing routine tumor destruction procedures.

Immunophotonics Announces 1st Patient Treated in Germany

Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in Germany at SLK Kliniken Heilbronn GmbH. The patient was treated as part of a multinational clinical trial sponsored by Immunophotonics (IP-IIO-622) that will assess the safety and efficacy of its lead asset, IP-001. The protocol has been approved by regulatory authorities in...

SACHS Forum and ASCO Annual Meeting in Chicago June 2 – 6, 2023

Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the SACHS 9th Annual Immuno-Oncology Innovation Forum, June 2, and the ASCO (American Society of Clinical Oncology) annual meeting, June 2 – 6.   They will be connecting with investors and clinical experts to discuss how Immunophotonics continues to...

Swiss Biotech Day 2023 April 24 & 25

Immunophotonics is pleased to announce its participation at the Swiss Biotech Day in Basel, Switzerland where VP of Business Development Theresa Visarius will present initial clinical and translational data on the use of IP-001 in solid tumor indications on April 24th in the Clinical Stage Development Companies session.

European Conference on Interventional Oncology (ECIO 2023) April 16 – 19

Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Booth 10 at the European Conference on Interventional Oncology (ECIO 2023) in Stockholm, Sweden, on April 16 – 19.  They are looking forward to connecting with clinical experts and learning from their experiences, as well as discussing how Immunophotonics continues...

Scroll to top